B
Bailisi Kang Biomedicine (Hangzhou)
Oncology biotherapeutics and tumor-targeting antibody-drug conjugates (ADCs)
About Bailisi Kang Biomedicine (Hangzhou)
Bailisi Kang Biomedicine, also known as Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (BlissBio), is a clinical-stage biopharmaceutical company founded in December 2017 by pharmaceutical veterans Dr. Ziping Wei and Yu Hong Zhou in Hangzhou, China. The company focuses on the discovery, development, and commercialization of anti-tumor biotherapeutics, with a specialization in antibody-drug conjugates (ADCs). The core team has experience in developing various biotherapeutics, including monoclonal antibodies, bispecific antibodies, and ADCs, with nine products they contributed to receiving market approval.
BlissBio's business model centers on its proprietary and patented ADC technology platform, developing a pipeline of oncology drugs to address unmet medical needs. The company has its own GMP-certified manufacturing facility capable of producing antibodies and ADCs for clinical trials and early-stage commercialization. Its revenue model involves strategic collaborations, licensing agreements, and milestone payments. A key partnership is with the Japanese pharmaceutical firm Eisai Co., Ltd. In May 2023, the two companies entered into a joint development and strategic collaboration agreement for BlissBio's leading product, BB-1701. The agreement includes upfront payments, milestone payments that could total up to $2 billion, and royalties on sales. Eisai gained global development and commercialization rights for BB-1701, excluding Greater China.
The company's main product candidate, BB-1701, is an ADC that targets the HER2 protein, which is expressed in various solid tumors like breast and lung cancer. It combines an anti-HER2 antibody with Eisai's anticancer agent, eribulin, as the payload. BB-1701 is currently in Phase I/II international clinical trials in the U.S. and China. The company's pipeline also includes other ADC candidates like BB-1705, which targets EGFR for solid tumors, and BB-1712, targeting B7-H3, both of which are in clinical development. BlissBio has successfully raised capital to fund its research and development, including a Series B round of $61.3M in April 2021 and a Series B++ financing from Eisai in June 2023.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 14.3/100
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jun 2023 | — | — | Eisai | ↗ |
| SERIES B✓Equity / VC | Jan 2023 | $14M | $55M | Sherpa Venture Partners · In Capital · Oriental Fortune Capital | ↗ |
Growth signals
Latest recorded traffic for Bailisi Kang Biomedicine (Hangzhou) is 90 monthly website visits, down 67.9% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Bailisi Kang Biomedicine (Hangzhou) in the Hangzhou ecosystem
The Bailisi Kang Biomedicine (Hangzhou) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
VMS Group- ICIn Capital
Sherpa Venture Partners
Oriental Fortune Capital
Eisai
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bailisi Kang Biomedicine (Hangzhou) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bailisi Kang Biomedicine (Hangzhou)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.